Comparing Impact of Panel Composition on Tumor Mutational Burden Calculation

November 15, 2019
Nicholas Bevins, MD, PhD

Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Nicholas Bevins, MD, PhD, a postgraduate resident at the University of California, San Diego, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden (TMB) calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo.

Clinicians at the University of California, San Diego, questioned what the difference was between different lab-based panels and Foundation Medicine panels, so investigators sought to compare how the different panel compositions may impact TMB.